High-Impact Nature Study—CRISPR Library Screening Unveils Synthetic Lethality Potential of PELO Gene in Two Cancer Subtypes

[Weekly News]: High-Impact Nature Study—CRISPR Library Screening Unveils Synthetic Lethality Potential of PELO Gene in Two Cancer Subtypes

CRISPR/Cas technology is a revolutionary tool in modern biological sciences, with applications spanning medicine, agriculture, environmental conservation, and more. New findings and case studies continue to emerge across these fields. Our‘CRISPR Weekly News’column brings you the latest research and industry updates. Here's a brief summary of the past week's highlights:

I. Research Updates

i. CRISPR Screening

1. Article Title: CRISPuRe-seq: pooled screening of barcoded ribonucleoprotein reporters reveals regulation of RNA polymerase III transcription by the integrated stress response via mTOR

Journal: Nucleic Acids Research (IF: 16.6)

Original Link：Click to view

Highlights:
The researchers developed the CRISPuRe-seq technique, uncovering that the integrated stress response (ISR) suppresses Pol III transcription by inhibiting mTORC1 and activating MAF1. This results in reduced tRNA synthesis and a coordinated decrease in protein synthesis, potentially offering new therapeutic avenues for certain diseases.

2. Article Title: A multiparametric anti-aging CRISPR screen uncovers a role for BAF in protein synthesis regulation

Journal: Nature Communications (IF: 14.7)

Original Link：Click to view

Highlights:
A genome-wide CRISPR screen identified 43 genes whose deletion alleviates progeroid cell phenotypes. The findings revealed that the BAF A12T mutation increases protein synthesis and translation errors, possibly contributing to the mechanisms underlying premature aging.

3. Article Title: CRISPR screening identifies regulators of enhancer-mediated androgen receptor transcription in advanced prostate cancer

Journal: Cell Reports (IF: 7.5)

Original Link：Click to view

Highlights:
Using CRISPR-Cas9 screening, the researchers identified HOXB13, GATA2, and TFAP2C as key transcription factors that regulate AR enhancer-mediated AR transcription. This discovery presents new therapeutic targets for advanced prostate cancer.

ii. CRISPR Detection

1.Article Title: Droplet pairing-merging enabled digital RPA-CRISPR/Cas12a (DIMERIC) assay for rapid and precise quantification of Hepatitis B Virus DNA

Journal: Biosensors and Bioelectronics（IF：10.7）

Original Link：Click to view

Highlights:
Researchers developed a microfluidic chip-based digital RPA-CRISPR/Cas12a (DIMERIC) detection method capable of quantifying nucleic acids in just 20 minutes, offering an effective tool for the rapid and precise quantification of pathogen nucleic acids.

2.Article Title: Molecular insights and rational engineering of a compact CRISPR-Cas effector Cas12h1 with a broad-spectrum PAM

Journal: Signal Transduction and Targeted Therapy (IF: 40.8)

Original Link：Click to view

Highlights:
Researchers performed an in-depth study of Cas12h1, discovering its broad-spectrum PAM recognition properties. By rational engineering, they developed a high-fidelity nucleic acid detector, Cas12h1hf, expanding the CRISPR toolbox for genome editing and molecular diagnostics.

3.Article Title: Low-background CRISPR/Cas12a sensing system with circular CRISPR RNA for amplified fluorescent detection of antibody in human serum

Journal: Talanta (IF: 5.6)

Original Link：Click to view

Highlights:

This study introduced a CRISPR/Cas12a-based sensing system using circular CRISPR RNA (CcrRNA) for high-sensitivity antibody detection in human serum, providing an efficient tool for detecting low-abundance biomarkers in complex biological samples.

iii. Other CRISPR-Related Research

1. Article Title: Reprogrammable RNA-targeting CRISPR systems evolved from RNA toxin-antitoxins

Journal: Cell (IF: 45.5)

Original Link：Click to view

Highlights:
Feng Zhang’s team revealed the evolutionary origins of the Cas13 system, showing it may have derived from the AbiF toxin-antitoxin system, thus providing an important foundation for the development of RNA editing tools.

2. Article Title: Customizable virus-like particles deliver CRISPR–Cas9 ribonucleoprotein for effective ocular neovascular and Huntington’s disease gene therapy

Journal: Nature Nanotechnology (IF: 14.7)

Original Link：Click to view

Highlights:
Researchers developed the RIDE platform, a cell-targeting programmable CRISPR-Cas9 ribonucleoprotein delivery system based on virus-like particles, which significantly alleviated disease symptoms in models of ocular neovascularization and Huntington’s disease, paving the way for in vivo CRISPR therapies.

II. Industry News

1. Gameto, a clinical-stage biotechnology company, announced that the FDA has approved its Phase 3 clinical trial for an induced pluripotent stem cell (iPSC)-based therapy. This milestone marks a major breakthrough for iPSC technology in reproductive medicine.

News Link: Click to view

2. Data from Accuredit and the First Affiliated Hospital of Bengbu Medical College showed that the in vivo gene editing product ART002 effectively and safely reduced low-density lipoprotein cholesterol (LDL-C) with a single dose in clinical trials for heterozygous familial hypercholesterolemia. This represents a significant breakthrough in in vivo gene editing for hypercholesterolemia treatment.

News Link: Click to view

EDITGENE focuses on CRISPR technology, offering a range of high-quality gene editing services and in vitro diagnostic products. These include but are not limited to: CRISPR Library Screening, Cell Line Engineering, Monoclonal Cell Line Screening, CRISPR Detection, We are committed to providing the most efficient technical services for CRISPR-related, gene function research, in vitro diagnostics, and therapeutic research.